You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 818 Combination therapy with anti-PD1 and anti-LAG3 leads to unique peripheral and intratumoral CD8+ T cells signatures in patients with metastatic melanoma

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
818 Combination therapy with anti-PD1 and anti-LAG3 leads to unique peripheral and intratumoral CD8+ T cells signatures in patients with metastatic melanoma
Free

Authors

Citation

Cillo A, Cardello C, Karapetyan L, et al
818 Combination therapy with anti-PD1 and anti-LAG3 leads to unique peripheral and intratumoral CD8+ T cells signatures in patients with metastatic melanoma
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0818

Publication history

  • First published November 7, 2022.
Online issue publication 
April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.